Table 4.
Duration and cost of treatment per treatment regimen
| Treatment regimen | LMBa | BFM | HOVONb | CODOX-M/IVAC | P value |
|---|---|---|---|---|---|
| N | 13 | 16 | 18 | 15 | |
| Median number of treatment days (range) | |||||
| Duration of treatment according to protocol | 217 | 168 | 105 | 84 | |
| Observed duration of treatment | 231 (193–319) | 171 (146–226) | 149 (121–215) | 95 (80–155) | < 0.001 |
| Planned number of inpatient days according to protocol | 129 | 147 | 66 | 84 | |
| Observed number of inpatient days | 102 (70–148) | 134 (100–169) | 63 (53–109) | 93 (75–130) | < 0.001 |
| Treatment costs in € | |||||
| Medication costs excluding rituximab | 5940 | 7702 | 11,272 | 9323 | |
| Rituximab | 7282 | 14,564 | 9103 | 10,923 | |
| Blood product transfusions | 14,964 | 5349 | 4838 | 16,204 | |
| Diagnostic procedures | 18,627 | 27,941 | 13,971 | 18,627 | |
| Inpatient days | 64,063 | 86,320 | 46,959 | 55,991 | |
| Autologous graft mobilization and harvestc | – | – | 5251 | – | |
| Total costs in € | 110,876 | 141,877 | 91,394 | 111,068 | |
aData shown for high risk protocol
bIncluding 3× RiCHOP
cCosts for daycare, medication, laboratory activities, and apheresis procedure related to mobilization/harvesting of autologous graft